The Online Investor
Ovid Therapeutics Inc (OVID)

Ovid Therapeutics is a biopharmaceutical company focused on developing medicines for patients and families living with rare neurological disorders. Co. is developing OV101 for the treatment of Angelman syndrome and Fragile X syndrome, two neurodevelopmental disorders that are characterized by similar symptoms, including sleep disorder, aberrant behavior, anxiety and cognitive or intellectual disabilities. Co. is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. OV935 is a potent, highly selective inhibitor of the enzyme cholesterol 24-hydroxylase.
Company Name: 
Ovid Therapeutics Inc
Drugs & Pharmaceuticals
Number of ETFs Holding OVID: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
Quotes delayed 20 minutes

Strong Buy (3.86 out of 4)
77th percentile
(ranked higher than approx. 77% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Ovid Therapeutics Inc (OVID) Page | The Online Investor Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.